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ABSTRACT
Objectives: To assess radiologist confidence in the characterization of suspicious breast 
lesions with a dedicated three-dimensional breast computed tomography (DBCT) 
system in comparison to diagnostic two-dimensional digital mammography (dxDM). 
Materials and Methods: Twenty women were recruited who were to undergo a breast 
biopsy for a Breast Imaging-Reporting and Data System (BI-RADS) 4 or 5 lesion 
evaluated with dxDM in this Institutional Review Board-approved study. The enrolled 
subjects underwent imaging of the breast(s) of concern using DBCT. Seven radiologists 
reviewed the cases. Each reader compared DBCT to the dxDM and was asked to 
specify the lesion type and BI-RADS score for each lesion and modality. They also 
compared lesion characteristics: Shape for masses or morphology for calcifications; 
and margins for masses or distribution for calcifications between the modalities using 
confidence scores (0–100). Results: Twenty-four biopsied lesions were included in 
this study: 17 (70.8%) masses and 7 (29.2%) calcifications. Eight (33.3%) lesions 
were malignant, and 16 (66.7%) were benign. Across all lesions, there was no 
significant difference in the margin/distribution (Δ = −0.99, P = 0.84) and shape/
morphology (Δ = −0.10, P = 0.98) visualization confidence scores of DBCT in relation 
to dxDM. However, analysis by lesion type showed a statistically significant increase in 
reader shape (Δ =11.34, P = 0.013) and margin (Δ =9.93, P = 0.023) visualization 
confidence with DBCT versus dxDM for masses and significant decrease in reader 
morphology (Δ = −29.95, P = 0.001) and distribution (Δ = −28.62, P = 0.002) 
visualization confidence for calcifications. Conclusion: Reader confidence in the 
characterization of suspicious masses is significantly improved with DBCT, but reduced 
for calcifications. Further study is needed to determine whether this technology can 
be used for breast cancer screening.
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INTRODUCTION
Breast cancer is the most common female cancer, except 
for skin cancer, in the United States for every major ethnic 
group and the second most common cause of cancer death 
in women.[1] Mammography continues to be the Gold 
Standard of screening women for breast cancer.[2‑4] Even 
with the development of full‑field digital mammography, 
the main limitation of mammography is its decreased 
sensitivity in women with dense breast tissue.[2‑7] Dense 
breast tissue is present in 40–60% of all women.[8‑10]
In reaction to this limitation, researchers have been 
investigating digital breast tomosynthesis (DBT).[11‑17] 
Published literature has demonstrated that DBT in 
combination with a conventional digital mammogram has 
demonstrated improved mass detection, decreased recall 
rates, and increased cancer detection.[11‑15] However, DBT 
has not eliminated mammographic breast compression.
Dedicated breast computed tomography (DBCT) is a new 
imaging modality that provides three‑dimensional (3D) 
data that can be reconstructed into multiple imaging 
planes. DBCT can be performed without breast compression 
and is not limited by breast density.[18‑21] The radiation dose 
level of DBCT is similar to the dose of a conventional 
two‑view mammogram.[17‑22] There is limited published 
data on DBCT breast lesion conspicuity and no published 
data on radiologist reader lesion confidence in clinical 
trials.[19‑23] Therefore, the objective of our study is to 
assess radiologist confidence in the characterization 
of suspicious breast lesions in a population of women 
going to biopsy with a DBCT system in comparison 




The procedures followed in this study were in accordance 
with the ethical standards of our Institutional Review 
Board (IRB) and with the Helsinki Declaration of 1975, as 
revised in 2000. In our IRB approved and Health Insurance 
Portability and Accountability Act (HIPPA)‑compliant study, 
all study subjects provided informed written consent 
after the nature of the study had been explained. In this 
prospective study, we recruited twenty consecutive women 
from our breast clinic who were scheduled to undergo a 
breast biopsy for a mammographically detected lesion 
that was evaluated with diagnostic 2D full‑field digital 
mammography (dxDM) from January 1, 2011 to October 
1, 2011. The inclusion criteria consisted of 40‑year‑old or 
older women, who were able to provide informed consent, 
had at least one detected mammographic abnormality 
that was confirmed as a Breast Imaging‑Reporting 
and Data System (BI‑RADS®) assessment category 4 or 
5 lesion after completion of diagnostic workup, and who 
were scheduled to undergo a core needle biopsy at our 
institution.[24] Women were not eligible for this study if 
they were under 40 years of age, weighed >350 pounds, 
were pregnant or lactating, had no mammographically 
evident lesion, or had a preexisting back, neck, shoulder, 
or general mobility difficulties. The enrolled subjects 
could have any breast composition category. After the 
DBCT imaging was complete, each subject was given a 
questionnaire to complete in order to evaluate her comfort 
level during DBCT imaging to that of other breast imaging 
scans on a continuous scale of 1 (much more comfortable) 
to 5 (much less comfortable).
Dedicated breast computed tomography scanner
The DBCT scans were performed using a prototype 
cone‑beam DBCT system designed and developed 
by ZumaTek, Inc. (Research Triangle Park, NC, USA). 
The system uses an ergonomically designed bed where 
the subject scanned lies prone, which is shown in 
Figure 1. The head of the scan bed consists of a custom 
formed patient support that allows for full breast and 
chest wall access while maximizing subject comfort and 
consequently, minimizing subject motion. The design of 
the scan bed allows one breast to be imaged at a time. 
The diameter of the patient table opening allows for a 
cylindrical imaging volume of 20 cm in diameter × 20 cm 
in height or 6283 cm3. The breast to be imaged is 
noncompressed and hangs pendant through the opening 
of the table in the imaging field below the scan bed, as 
denoted by the arrow in Figure 1. In addition, there are 
radiation shielded panels all around the bed that can 
be opened below the head of the scanning bed that 
can allow the imaging technologist direct visualization 
if further positioning of the subject as needed. Besides 
direct visualization, there is also a laser site that can aid 
with positioning. There is an enclosure containing the 
imaging hardware also beneath the bed.
Figure 1: Three-dimensional dedicated breast computed tomography prototype 
system. (a) Ergonomically designed bed where the subject scanned lies 
prone. (b) The noncompressed breast to be imaged hangs pendant through 
the opening of the table (arrow) below the scan bed.
ba
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This cone‑beam CT system features a single 30 cm × 30 cm, 
amorphous silicon flat‑panel, digital detector with a 
Thallium‑doped Cesium Iodide scintillator (PaxScan® 3030, 
Varian Medical Systems, Palo Alto, California, USA). The 
detector has 197‑micron pixels, which can be binned in 2 × 2 
or read out in 1 × 1 mode. The pixel depth is 14‑bits. The system 
uses a rotating tungsten rotating anode (RAD‑70B, Varian 
Medical Systems, Palo Alto, California, USA) with a tungsten 
filter. The nominal focal spot size is 0.3 mm. The tube is capable 
of an output to 49 kVp. The DBCT system is powered by a 
high‑frequency X‑ray generator (SEDECAL, Madrid, Spain), 
which allows for fast pulsed X‑ray generation up to 30 frames 
per second. The X‑ray tube and detector are fixed at a specific 
source‑to‑image distance of 70 cm; therefore, there is no 
contact with the breast being imaged. The scanner operates in 
step and shoot mode whereby it is preprogrammed to move 
and stop at 300 specific positions around the noncompressed, 
pendant breast as individual images are taken. The scan 
time for one breast is 1 min 40 s. The average radiation dose 
is <4.5 mGy for a bilateral DBCT scan.[21]
Motors in the system provide motion to allow the imaging 
components to be moved about a full 360° vertical rotation 
axis, and also 60° horizontal pivoting about the rotation 
axis is achieved around the noncompressed breast being 
imaged. This unique 3D orbiting capability allows for full 
breast and chest wall access with more complete cone 
beam sampling throughout the image volume.[21] In 
addition to a horizontal rotation, the system is also able 
to tilt. This is necessary in order to remove cone beam 
distortion artifacts. A third motion is possible to allow the 
system to be moved vertically up and down to position the 
system optimally below the bed.
At the end of the scan, the 300 images obtained for each 
breast are sent to a computer processing workstation and 
are automatically processed with an iterative reconstruction 
algorithm that reconstructs (768 × 768 × 14 bits/projection) 
the images into a 3D DBCT dataset. The measured isotropic 
reconstructed pixels are 197 microns, and the measured 
reconstructed resolution of the line pairs with a 20 cm 
diameter Catphan phantom  (Phantom Laboratory, 
Salem, NY, USA) is 2.5 line pairs per millimeter. Prior to 
the reconstruction, motion correction software may be 
utilized. The resulting Digital Imaging and Communication 
in Medicine (DICOM) compliant images were viewed 
using ClearCanvas software  (ClearCanvas, Toronto, 
Ontario, Canada). The DBCT data was displayed in three 
simultaneous imaging planes (coronal, sagittal, and axial 
planes), Figure 2. In addition, the slice thickness and other 
viewing features, such as window and leveling, could be 
adjusted on the viewing workstation.
Training and start up
The principal investigator (PI) and the research technologist, 
certified in mammography, were both trained on the 3D 
DBCT system and workstation by application and technical 
supervising personnel from ZumaTek, Inc., including how 
to use, acquire and transmit the DBCT images. For training 
purposes in this internal IRB approved and HIPPA‑compliant 
study, five healthy volunteers were recruited prior to study 
accrual. The healthy volunteers had to be at least 40 years 
old, able to provide informed consent, and had a normal 
current (<60 days) mammogram. A healthy volunteer 
was excluded if she was <40 years of age, weighed >350 
pounds, pregnant or lactating, had preexisting back, 
neck, shoulder, or general mobility difficulties, and did 
not have a mammogram within 60 days or the recent 
mammogram study was abnormal. All of the healthy 
volunteers provided informed consent. If the healthy 
volunteer was of childbearing age and not surgically sterile, 
a urine pregnancy test was performed to exclude the 
possibility of pregnancy prior to DBCT imaging. The 
healthy volunteers underwent bilateral imaging with the 
DBCT system only to test the operation of the system, to 
make any necessary adjustments to the system, and to 
train the technologist who operated the system. Images of 
all healthy volunteers were reviewed jointly by our study 
investigators and sponsor quality control personnel to 
review image quality.
Figure 2: 54-year-old women with a mass in the medial right breast diagnosed 
with a fibroadenoma. Dedicated breast computed tomography images viewed 
as three-dimensional data sets in multiple imaging planes (coronal, sagittal and 
axial planes) on a softcopy workstation demonstrate a 1 cm, oval, predominately 
circumscribed, noncalcified mass (arrow).
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Image acquisition
Eligible subjects were identified by research staff review of 
the clinical reports of women who were scheduled for at least 
one image‑guided needle core breast biopsy. All diagnostic 
2D digital mammographic images (dxDM) with additional 
magnification views as clinically needed (Senographe 
Essential, General Electric Medical, Milwaukee, WI, USA) 
of all the eligible subjects were reviewed by the PI of the 
study prior to contacting potential subjects to ensure that 
the lesion recommended for biopsy was visualized on the 
dxDM exam.
All eligible women who agreed to participate in the study 
were asked to come to our imaging research laboratory 
prior to their scheduled biopsy appointment to complete 
the informed consent process and to undergo the study 
DBCT scan. For subjects of childbearing age, a negative 
urine pregnancy test was required prior to enrollment. The 
enrolled subjects subsequently underwent imaging of the 
breast(s) recommended for biopsy using the DBCT system.
The subjects were imaged in the prone position. One breast 
at a time was placed in the table opening near the head 
of the table, and the noncompressed breast was allowed 
to hang pendant for the scan in the imaging field of view. 
Prior to starting the scan, the technologist confirmed 
that the subject’s breast to be imaged was centered in 
the device from below the table. The technologist then 
closed the observation panels, asked the subject to relax 
and remain still, and commenced with the DBCT scan. 
The actual scan time was 1 min 40 s per breast. During 
imaging, the patient was allowed to breathe normally. 
If the patient had a qualifying lesion in the contralateral 
breast that breast was also positioned and scanned in the 
same manner. The procedure to scan the opposite breast 
was performed without the subject having to leave the 
scanning bed. Once DBCT imaging was finished, the study 
procedure was complete. The DBCT images were reviewed 
by the PI of the study and research technologist to ensure 
image quality. Afterward, the enrolled study subjects were 
asked to complete a questionnaire about the comfort of 
the DBCT machine.
Postimaging
Subsequently, the breast biopsy took place as clinically 
indicated. The research DBCT exam was not interpreted 
prior to the conductance of the breast biopsy and, 
therefore, did not influence clinical decision‑making.
Data submission
The research technologist electronically submitted to 
our medical imaging laboratory all de‑identified clinical 
report forms as well as the de‑identified breast CT exams, 
mammograms, breast ultrasounds (if available), and 
breast magnetic resonance imaging (MRI) (if available) 
of all eligible enrolled subjects that were obtained and 
contributed to the ultimate diagnosis leading to biopsy. 
The transmitted de‑identified data were reviewed and 
correlated with the imaging findings, entered, and prepared 
for inclusion in the reader study.
Reader study
A reader study was conducted after the completion of 
patient accrual to the study to compare the visibility of 
lesion characteristics with the DBCT compared to 2D 
full‑field digital screening mammography and diagnostic 
mammography images. Seven breast imaging radiologists 
reviewed the cases in the reader study. For training 
purposes, each radiologist was initially presented with 
four cases in order to become familiar with the workstation 
design, image display, and lesion examples. The training 
cases consisted of a mixture of benign and malignant 
cases with different lesion types with lesion descriptors. 
The study cases were presented in random order for each 
reader. The breast lesions were annotated on all images 
of each case for each modality for the readers by the PI of 
the study. The DBCT data was displayed in coronal, sagittal, 
and axial planes, and the dxDM data were displayed on 
dedicated workstations. The radiologists were allowed 
to roam, zoom, window, and level all the images in either 
modality if desired. In addition, the viewing software for 
DBCT allowed the radiologist to adjust slice thickness of the 
images and multi‑intensity projection images could also 
be used as part of the software display for interpretation.
The study consisted of the DBCT and mammography 
exams presented side‑by‑side for a given case. All lesions 
in this study regardless of lesion type were visible on both 
modalities. Each reader was asked to compare side‑by‑side 
the DBCT exam to the dxDM exam including the lesion 
recommended for biopsy. Each reader was asked to 
specify the lesion type and BI‑RADS® assessment category 
for each lesion for each modality and to compare the 
lesion characteristics: Shape for masses or morphology 
for calcifications and margins for masses or distribution for 
calcifications between the two modalities using confidence 
scores (0–100). The specific descriptors that were used for 
lesion characteristics were consistent with the BI‑RADS® 
mammography lexicon and were used consistently 
amongst the readers.[24]
Statistical analysis
Statistical analysis was performed with SAS statistical 
software, version PC 9.2 (SAS Institute, Inc., Cary, NC, USA). 
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The average confidence scores of each modality over the 
seven readers for each condition were calculated, and a 
linear mixed effects model was used to analyze the data. 
A random intercept was used in the model to account for 
the correlation among readers when reading the images 
from the same subject. The Wald’s test, based on the model 
fit, was used to test whether the grand mean parameter 
was larger than zero. P < 0.05 was considered to indicate 
statistically significant differences.
RESULTS
There were a total of 24 biopsied lesions in 20 subjects 
included in this study.
Each patient underwent percutaneous biopsy, and the 
pathology reports were reviewed and correlated with 
the imaging findings. The mammographic findings of 
the biopsied lesions consisted of 17 (70.8%) masses and 
7 (29.2%) calcifications. Overall, 8 (28.6%) lesions were 
malignant, and 16 (71.4%) were benign. Six (75.0%) of 
the malignant lesions (5 invasive cancers and 1 ductal 
carcinoma in situ [DCIS]) were presented as masses. Only 
2 (28.6%) of the 7 cases of calcifications were malignant, 
both DCIS. The mean size of a malignant mass case and a 
malignant calcification case was 2.8 cm (range 1.0–4.5 cm) 
and 4.3 cm (range 1.5–7.0 cm), respectively. The mean 
size of a benign mass case was 1.5 cm (range 0.4–2.5 cm), 
and the mean size of a benign calcification case was 
1.8 cm (range 0.5–3.0 cm). Mammographic lesion type, size, 
and pathology are listed in Table 1.
Three (15%) subjects had bilateral lesions and 1 (5.0%) 
subject had 2 lesions in the same breast. Of the 3 subjects 
with bilateral lesions, 1 (33.3%) subject had bilateral 
invasive cancer, and the other 2 (66.7%) subjects had 
unilateral cancer (1 case invasive and 1 case DCIS) with 
a contralateral benign lesion. The one (5.0%) subject 
with 2 lesions in the same breast had both a malignant 
lesion (DCIS) and a benign lesion (fibroadenoma). With 
regard to breast side of the lesion, 10 (41.7%) were located 
in the right breast, and 14 (58.3%) were located in the left 
breast. Three (37.5%) malignant lesions were located in the 
right breast, and 5 (62.5%) were located in the left breast.
The 20 subjects enrolled and imaged in the study consisted 
of 12 (60.0%) Caucasian and 8 (40.0%) African American 
women with a mean age of 58.0 years (range 41–75 years). 
The mean age of a subject with a malignant lesion was 
56.5 years and the mean age of a subject with a benign 
lesion was 58.0 years. Six (30.0%) of the subjects had a 
history of a benign biopsy: 3 (50.0%) core needle biopsy 
and 3 (50.0%) open surgical excision. One (5.0%) subject 
had a prior breast cancer history of DCIS that had been 
treated with a mastectomy. None of the subjects had a 
family history of breast cancer.
The BI‑RADS® mammographic breast composition 
categories for the enrolled subjects were 8 (40.0%) with 
scattered areas of fibroglandular density, 9 (45.0%) with 
heterogeneously dense, and 3 (15.0%) with extremely 
dense breasts, Table 1. When the latter two categories 
are combined, 60.0% of the cases were in subjects with 
dense breast tissue. None of the subjects had almost 
entirely fatty breast composition. For the 7 (35.0%) subjects 
diagnosed with at least 1 cancer (1 subject had a bilateral 
invasive cancer), the BI‑RADS® mammographic breast 
composition categories were 3 (42.9%) with scattered 
areas of fibroglandular density, 3 (42.9%) heterogeneously 
dense, and 1 (14.2%) with extremely dense breasts. The 
one (14.3%) subject with the bilateral breast cancer had 
heterogeneously dense breasts. The two (28.6%) subjects 
that had cancer (DCIS) present as calcifications had the 
mammographic breast composition of scattered areas of 
fibroglandular density. For the 13 (65.0%) subjects with 
benign only pathology, 5 (38.5%) had scattered areas of 
fibroglandular density, 6 (46.2%) had heterogeneously 
dense breasts, and 2 (15.3%) had extremely dense breasts 
mammographically.
A total of seven radiologists reviewed the cases in a reader’s 
study. All radiologists were fellowship trained in breast 
imaging. Their mean years of experience interpreting 
mammography was 8 (range 3–14 years). All radiologists 
were certified by the American Board of Radiology and met 
accreditation standards mandated by the Mammography 
Quality Standard Act and Program. None of the radiologists 
had prior DBCT research experience or clinical experience 
in interpretation of DBCT.
Mean confidence radiologist reader scores of DBCT 
compared to dxDM for the two conditions for all lesions 
regardless of lesion type, lesion pathology, and subject breast 
density are shown in Table 2. Across all lesions, there was no 
significant difference in the margin/distribution (Δ = −0.99, 
P = 0.84) and shape/morphology (Δ = −0.10, P = 0.98) 
visualization confidence scores of CT in relation to dxDM. 
However, analysis by lesion type showed a statistically 
significant increase in reader shape (Δ =11.34, P = 0.013) 
and margin (Δ =9.93, P = 0.023) visualization confidence 
with CT versus dxDM for masses and significant decrease in 
reader morphology (Δ = −29.95, P = 0.001) and distribution 
(Δ = −28.62, P = 0.002) visualization confidence for 
calcifications, Table 3. The reader visualization confidence 
scores of benign and malignant lesions between the two 
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modalities for subjects with dense breast tissue were not 
significantly different (P > 0.1). There was no significant 
difference (P > 0.1) between the two modalities in the 
readers’ BI‑RADS assessment scores across all lesions, 
regardless of size or final pathology or subject breast 
density. Examples of a benign and a malignant mass with 
mammographic and DBCT correlation images are shown in 
Figures 3 and 4, respectively. In addition, mammographic 
and DBT correlation images for benign and malignant 
calcifications cases are demonstrated in Figures 5 and 6.












1 HD 1 Mass 2.5 Benign FCCs with fragment of cyst wall
2 HD 2 Mass 1.0 Benign Fibroadenoma
3 HD 3 Calcifications 2.4 Benign FCCs with SA with associated calcifications
4 HD 4 Mass 0.4 Benign FCCs with SA
5 SF 5 Mass 1.8 Benign FCCs with fat necrosis and hemorrhage
6 HD 6 Mass 1.0 Benign FCCs with BBT
6 HD 7 Mass 4.5 Malignant IDCa, Grade II
7 HD 8 Mass 1.5 Malignant IDCa with lobular features, Grade I; DCIS, 
nuclear Grade II, solid type
8 ED 9 Mass 1.5 Benign FCCs with BBT
9 SF 10 Mass 0.7 Benign Fibroadenoma
10 SF 11 Mass 1.4 Benign Acute inflammation with foreign body reaction 
and granulation tissue
11 ED 12 Calcifications 0.5 Benign FCCs with PASH with associated calcifications
12 SF 13 Mass 3.2 Malignant IDCa with Mucinous features, Grade I
12 SF 14 Mass 0.9 Benign Lymph node
13 HD 15 Calcifications 0.5 Benign FCCs with associated calcifications
14 SF 16 Mass 1.0 Malignant DCIS, nuclear Grade III, solid type
15 HD 17 Mass 3.0 Malignant IDCa, Grade I; DCIS, nuclear Grade I, solid and 
cribriform type
15 HD 18 Mass 3.3 Malignant IDCa with lobular features, Grade I
16 SF 19 Calcifications 7.0 Malignant DCIS, nuclear Grade III, comedo type with 
necrosis and associated calcifications
16 SF 20 Mass 1.0 Benign Fibroadenoma
17 SF 21 Calcifications 1.5 Malignant DCIS, nuclear Grade II, cribriform and 
micropapillary type with associated 
calcifications
18 ED 22 Calcifications 3.0 Benign SA, fibroadenomtous change, dense fibrosis 
with associated calcifications
19 HD 23 Mass 1.8 Benign FCCs with SA, dense fibrosis
20 SF 24 Calcifications 0.5 Benign FCCs with associated calcifications in benign 
ducts
SF: Scattered areas of fibroglandular density, HD: Heterogeneously dense, ED: Extremely dense, FCCs: Fibrocystic changes, SA: Sclerosing adenosis, IDCa: Invasive ductal carcinoma, not 
otherwise specified, DCIS: Ductal carcinoma in situ, BBT: Benign breast tissue, PASH: Pseudoangiomatous stromal hyperplasia
Table 2: Reader confidence scores all lesions data
Feature score Overall Reader 1 Reader 2 Reader 3 Reader 4 Reader 5 Reader 6 Reader 7 Estimated difference P


































The numbers outside the parentheses are the average scores, the numbers inside the parentheses are the standard deviation
Table 3: Reader confidence scores by lesion type
Lesion type Outcome Overall Reader 1 Reader 2 Reader 3 Reader 4 Reader 5 Reader 6 Reader 7 Estimated 
difference
P




































































The numbers outside the parentheses are the average scores, the numbers inside the parentheses are the standard deviation
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Figure 3: 49‑year‑old women with a mass in the medial right breast diagnosed with a fibroadenoma. Mammographic images of the right breast: (a) craniocaudal, 
(b) mediolateral oblique, (c) spot compression magnification craniocaudal view, (d) spot compression magnification mediolateral oblique view. The mammographic 
images demonstrate a 1 cm, oval, obscured mass (arrow) in the upper inner quadrant. Dedicated breast computed tomography slice images of the right breast: 
(e) axial, (f) sagittal, (g) coronal, (h) enlarged sagittal image. The dedicated breast computed tomography images of the mass (arrow) show a circumscribed margin 









Figure 4: 72‑year‑old women with a mass in the medial left breast diagnosed with invasive ductal carcinoma. Mammographic images of the left breast: (a) mediolateral 
oblique, (b) craniocaudal, (c) spot compression magnification mediolateral oblique view, (d) spot compression magnification craniocaudal view. The mammographic 
images show a 1.5 cm, irregular, partially obscured mass (arrow) in the medial aspect. Dedicated breast computed tomography slice images of the left breast: 
(e) sagittal, (f) axial, (g) coronal, (h) enlarged axial image. The dedicated breast computed tomography images of the mass (arrow) demonstrate that the margins of 
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The total number of mammographic images was also 
recorded for this study. For the 20 subjects, the mean 
number of images obtained for each subject’s diagnostic 
mammogram exam was 6 (range 2–10). Nine (45.0%) 
subjects initially underwent a diagnostic mammogram. For 
the 11 (55.0%) subjects that originally underwent a screening 
mammogram and were “recalled” for further diagnostic 
evaluation, the mean number of both mammographic 
exam images acquired were 10 (range 6–16). In contrast, 
only 1 DBCT scan was obtained per index breast per subject 
in this research study.
Results of the study subject questionnaire after completion 
of the DBCT portion of the study demonstrate that all 
20 (100%) subjects were satisfied or very satisfied with 
the DBCT scan. Thirteen (65.0%) subjects reported no 
discomfort and 6 (30.0%) subjects reported minimal to mild 
discomfort during DBCT scanning. Only 1 (5.0%) subject 
reported moderate discomfort during the DBCT scanning. 
All discomfort that was reported was related to neck, back, 
or abdomen from the scanning table or arm positioning. In 
regard to scanning time and noise level of the DBCT device, 
19 (95.0%) and 19 (95.0%) of the subjects were satisfied or 
very satisfied, respectively.
Questionnaire results of subject comfort of a DBCT scan 
versus a mammogram, handheld breast ultrasound (HHBUS), 
and contrast enhanced‑MRI (CE‑MRI) of the breasts were 
also collected. All 20 (100%) of the subjects reported the 
DBCT scan to be more comfortable than a mammogram. 
Sixty‑five percent (13 subjects) reported the DBCT scan 
was more comfortable than HHBUS. Thirty‑five percent 
(7 subjects) reported the DBCT scan and HHBUS to be equal 
in comfort. One (5%) subject reported the DBCT scan was less 
comfortable than a CE‑MRI, and one (5%) subject reported 
the DBCT scan and the CE‑MRI to be equal in comfort.
DISCUSSION
Our initial clinical experience with a prototype 3D DBCT 
system demonstrates that overall radiologist reader 
confidence in the characterization of suspicious lesions 
recommended for biopsy is similar to that of diagnostic 
2D digital mammography. Radiologists were significantly 
more confident in mass shape and margin characterization 
on DBCT images compared to 2D digital diagnostic 
mammography. Even though all calcification lesions were 
visible on the DBCT, reader confidence in calcification 
lesion characteristics was significantly less than diagnostic 
mammography, and this may have been related to 
our prototype DBCT system. The DBCT system used 
197‑micron pixels in contrast to digital mammography 
that may have pixel sizes between 50 and 100 microns 
depending on the manufacturer. Our study used a digital 
mammography system with 100‑micron pixels in addition 
to a magnification factor of ×1.8 for the spot compression 
magnification views. Thus, improvements in DBCT detector 
resolution and specific postprocessing algorithms could 
help radiologists improve calcification characterization.
Figure 5: 48‑year‑old women with grouped calcifications in the medial left 
breast diagnosed with fibrocystic changes with associated calcifications. 
Mammographic images of the left breast: (a) spot compression magnification 
craniocaudal view, (b) 90° spot compression magnification view. The 
mammographic images demonstrate 1.5 cm, grouped, coarse heterogeneous 
and round calcifications (arrow). Dedicated breast computed tomography slice 
images: (c) axial image, (d) enlarged axial image, (e) enlarged sagittal image. 
The dedicated breast computed tomography images of the calcifications (arrow) 




Figure 6: 60‑year‑old women with calcifications in the medial left breast diagnosed with ductal carcinoma in situ. Mammographic images of the left breast: (a) spot 
compression magnification craniocaudal view, (b) 90° spot compression magnification view. The mammographic images show fine linear calcifications in a segmental 
distribution spanning 7 cm (arrow). Dedicated breast computed tomography slice images: (c) axial, (d) sagittal, (e) enlarged axial view, (f) enlarged sagittal view. The 
dedicated breast computed tomography images also demonstrate the same abnormal calcifications and distribution (arrow) as the mammographic images.
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The increase in reader confidence with masses on DBCT 
is most likely the result of DBCT’s 3D imaging capability. 
With 3D imaging of the breast, DBCT has the advantage of 
being able to remove tissue overlap (masking) through the 
use of tomographic slice sections. In addition, the acquired 
image data obtained by DBCT is used to reconstruct a 
volume dataset for image display and can provide further 
diagnostic information for the radiologist. Since DBCT is 
true 3D imaging and does not require breast compression, 
it allows for registered orthogonal views of the breast in 
any projection for viewing, similar to MRI of the breast. The 
viewing software allows the radiologist to review images 
and lesions in multiple planes and adjust slice thickness of 
the images for interpretation. In addition, a multi‑intensity 
projection image can also be visualized as part of the 
software display. Consequently, these advantages of DBCT 
may improve lesion characterization, which may aid in 
decreasing unnecessary biopsies and could possibly help in 
surgical planning in patients diagnosed with breast cancer.
The results of our study support the initial work by Lindfors 
et al., in which they evaluated BI‑RADS® 4 and 5 lesions with 
their prototype DBCT system.[19] Their study consisted of 
67 lesions: 52 (77.6%) masses, 12 (17.9%) calcifications, 
and 3 (4.5%) other types. However, 9 (13.4%) of 67 lesions 
in their study were not seen on DBCT. Overall, their 
results showed that breast CT was equal to screen film 
mammography for visualization of breast lesions. In 
addition, breast CT was significantly better than film‑screen 
mammography for visualization of masses (P < 0.002) but 
film‑screen mammography out‑performed breast CT for 
visualization of calcifications (P < 0.006).[19] In contrast to 
their study, our subjects’ mammographic images were 
acquired with 2D full‑field digital mammography, and we 
evaluated not only the reader confidence of lesion type but 
also confidence of lesion characteristics.
In the study by O’Connell and Kawakyu‑O’Connor, two 
radiologists evaluated 36 patients with 37 abnormal 
mammographic and/or ultrasound categorized as BI‑RADS® 
4 or 5 lesions that were evaluated with their prototype DBCT 
system prior to biopsy.[22] Thirty‑three (89.2%) of 37 breasts 
demonstrated a mammographic abnormality. Their results 
demonstrated a high degree of correlation between the 
DBCT and digital mammography across a variety of lesion 
types with 33 of 34 (97.1%) mammographic lesions being 
scored as equal or better visualized on breast CT relative 
to diagnostic mammography. Only one (2.9%) lesion in 
their study was not seen on DBCT and was attributed to 
be a mammographic summation shadow (22). Unlike their 
study criteria, all of our study lesions were visible with both 
diagnostic 2D digital mammography and DBCT. We did not 
include any lesions visible on sonography since we were 
comparing DBCT to diagnostic 2D digital mammography. 
In addition, our reader study included five more radiologists 
and also evaluated lesion features. The study by O’Connell 
et al., reported that 10.4% of their calcification findings 
were not seen on their prototype DBCT system.[20] All (100%) 
calcification lesions were visualized with DBCT in our 
study; however, radiologist confidence in calcification 
characterization was significantly better with digital 
diagnostic mammography.
3D DBCT may have several potential advantages compared 
to digital mammography in a diagnostic setting. The 
first advantage is radiation exposure during imaging. 
Currently, there is no maximum limit of breast radiation 
exposure with diagnostic mammography. Only screening 
2D mammography and DBT have dose limits.[25] As with 
the prototype DBCT system we used, DBCT radiation doses 
similar to those with two‑view mammography are being 
targeted.[18‑23,25] The DBCT radiation dose is equivalent to 
about 2 months of natural background radiation exposure 
by a person in 1 year in the United States.[21] Comparable 
to mammographic doses, the radiation doses from DBCT 
are largely restricted to breast tissue.
The second advantage of the DBCT system is that the 
automated images of the uncompressed breast are 
obtained in a standardized manner with a short acquisition 
time. The DBCT scan time was 1 min 40 s in our study 
and was comparable to other published studies.[19‑23] 
Another benefit of our system is that due to the design 
of the imaging device even subjects with a large breast 
size (EE cup size) can be imaged without excluding breast 
tissue. Finally, DBCT is well tolerated. Our results support 
other studies in which higher degrees of subject comfort 
in the DBCT examination relative to mammography were 
reported.[19‑22]
Limitations
There were some limitations to our study. First, none of 
the readers had prior research or clinical experience in 
interpretation of DBCT images. Another limitation was 
that only a small sample size of different lesion types 
was included in this single site study in which enrolled 
subjects had undergone a standard of care 2D digital 
mammographic diagnostic workup prior to being enrolled 
in this research study. None of the subjects had DBT since 
this was not available at our institution at the time of this 
study. Moreover, the resolution of the detector used on 
our prototype DBCT system was less than a full‑field digital 
mammogram. Finally, our DBCT images were obtained 
without contrast but rather with a beam to optimize 
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contrast differences between adipose and glandular tissues. 
The results of the study may have differed if the radiologists 
had DBCT experience, a larger sample size, DBT use, a 
prototype DBCT system with a finer spatial resolution and 
dedicated image processing algorithms and possibly the 
administration of intravenous contrast.[23] Nevertheless, 
future studies are needed in evaluating noncontrast DBCT 
versus contrast DBCT and DBT.
CONCLUSION
Dedicated 3D breast computed tomography is a novel 
well‑tolerated imaging modality that allows for true isotropic, 
3D imaging of the breast without mammographic compression. 
DBCT is comparable to conventional mammography in terms 
of radiation dose and overall lesion visibility. DBCT is superior 
in radiologists’ visualization and characterization of masses, 
but inferior to diagnostic mammography for calcifications. 
Its application could help eliminate the 2D mammographic 
limitation of overlapping tissue. Technical challenges remain, 
but 3D DBCT may have potential clinical applications in breast 
cancer screening and diagnosis.
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